Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine in humans

Gastroenterology

Volumn 104, Issue 6, 1993, Pages 1832-1847

  Bjarnason, Ingvar ^a   Hayllar, Jeremy ^a   Macpherson, A N drew J ^a   Russell, A N thony S ^b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; DICLOFENAC; FENBUFEN; FLUFENAMIC ACID; IBUPROFEN; INDOMETACIN; MEFENAMIC ACID; METRONIDAZOLE; MISOPROSTOL; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; SALAZOSULFAPYRIDINE;

COLITIS; COLLAGEN DISEASE; COLON DIVERTICULOSIS; DRUG INDUCED DISEASE; ENTERITIS; ENTEROPATHY; EOSINOPHILIC ENTERITIS; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; HUMAN; INTESTINE MUCOSA PERMEABILITY; INTESTINE ULCER; MALABSORPTION; ORAL DRUG ADMINISTRATION; OSTEOARTHRITIS; PRIORITY JOURNAL; PROCTITIS; PROTEIN DEPLETION; PSEUDOMEMBRANOUS COLITIS; RECTAL DRUG ADMINISTRATION; RELAPSE; REVIEW; RHEUMATOID ARTHRITIS; SMALL INTESTINE OBSTRUCTION; SMALL INTESTINE PERFORATION; SUSTAINED RELEASE PREPARATION;

ANIMAL; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLON; ENTERITIS; HUMAN; INTESTINAL DISEASES; INTESTINAL PERFORATION; INTESTINE, LARGE; INTESTINE, SMALL; PERMEABILITY;

EID: 0027244454     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1016/0016-5085(93)90667-2     Document Type: Review

References (229)

1. Nonsteroidal antiinflammatory drugs-another look
2. Current controversies in rheumatology. Controversies in detection and management of non-steroidal anti-inflammatory drug induced side effects on upper gastrointestinal tract
3. Rheumatoid arthritis
4. Aspirin use in patients with major gastrointestinal bleeding and peptic ulceration
5. Aspirin in chronic gastric ulcer: an Australian experience
6. An endoscopic evaluation of the effects of non-steroidal anti-inflammatory agents on the gastric mucosa
7. Non-steroidal anti-inflammatory drug gastropathy recognition and response
8. Upper gastrointestinal disease in rheumatoid arthritis
9. Comparison of the effects of regular and enteric-coated aspirin on gastroduodenal mucosa in man
10. Contrasting presentation and findings between patients with rheumatic complaints taking non-steroidal anti-inflammatory drugs and a general population referred to endoscopy
11. Epidemiological evidence on the association between peptic ulceration and antiinflammatory drugs
12. The relationship between NSAID use and peptic ulcer disease
13. Prevention of non-steroidal antiinflammatory drug induced gastric ulceration with Misoprostol; multicenter, double blind placebo controlled trial
14. Gastroprotection and non-steroidal anti-inflammatory drugs
15. Effects of aspirin on the human stomach in normals. Endoscopic comparison of damage produced at 1 hour, 24 hours and 2 weeks after administration
16. Endoscopic evaluation of cimethidine and sucralfate for prevention of naproxen-induced gastroduodenal injury: effects of scoring method
17. Gastroscopic findings after therapy with nonsteroidal anti-inflammatory drugs
18. Endoscopic and microscopic findings in symptomatic and asymptomatic patients on long term nonsteroidal anti-inflammatory drug treatment (abstr)
19. Chronic gastritis—a pathogenic approach
20. Reflux gastritis in the intact stomach
21. Chemical gastritis and Helicobacter pylori related gastritis in patients receiving nonsteroidal anti-inflammatory drugs: Comparison and correlation with peptic ulceration
22. Gastritis-histopathological background
23. Misoprostol in the prevention and healing of NSAID-associated gastric and duodenal mucosal damage
24. Non-steroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons
25. Non-steroidal anti-inflammatory drug-induced ulcers: management by traditional therapies
26. Non-steroidal anti-inflammatory drugs and bleeding peptic ulcer
27. NSAID use and death from peptic ulcer in the elderly
28. The relationship of upper gastrointestinal bleeding to NSAID and aspirin: a case control study
29. Rising frequency of ulcer perforation in elderly people in the U.K.
30. Gastrointestinal events in patients prescribed NSAIDs: a controlled study using record linkage in Tayside
31. Nonsteroidal anti-inflammatory drugs and life threatening complications of peptic ulcer disease
32. Enteritis and colitis associated with mefenamic acid
33. Mefenamic acid enteropathy
34. Enteritis and colitis associated with mefenamic acid
35. Enteritis and colitis associated with mefenamic acid
36. Enteritis and colitis associated with mefenamic acid
37. A case of meclofenamate sodium-induced colitis
38. Enteritis and colitis associated with mefenamic acid
39. Colitis caused by NSAID
40. Colonic inflammation and NSAID administration
41. Colitis associated with ibuprofen (letter)
42. Proctocolitis induced by salicylate and associated with asthma and recurrent nasal polyps (letter)
43. Proctocolitis induced by salicylates (letter)
44. Acute eosinophilic colitis and hypersensitivity reaction associated with naproxen therapy
45. Diclofenac-induced pseudomembraneous colitis
46. Collagenous colitis in the setting of Nonsteroidal anti-inflammatory drugs and antibiotics
47. Non-steroidal anti-inflammatory drugs and the bowel
48. Nonsteroidal anti-inflammatory drugs as a possible cause of collagenous colitis (abstr)
49. Ileocolonoscopic findings in seronegative spondyloarthropathies
50. HLA-B27 related arthritis and bowel inflammation. Part 2. Ileocolonoscopy and bowel histology in patients with HLA-B27 related arthritis
51. Gut inflammation in the pathogenesis of idiopathic forms of reactive arthritis and in the peripheral joint involvement of ankylosing spondilitis
52. Histopathology of intestinal inflammation related to reactive arthritis
53. Ulcer of the caecum during oxyphenylbutazone (Tanderil) therapy
54. Ibuprofen and benign cecal ulcer
55. Ulceration of the colon associated with naproxen and acetylsalicylic acid treatment
56. Benign ulcer of sigmoid colon
57. Colonic ulceration and bleeding during diclofenac therapy (letter)
58. Colitis induced by nonsteroidal anti-inflammatory drugs
59. Benign cecal ulcers
60. Use of anti-inflammatory drugs by patients with small or large bowel perforation and haemorrhage
61. Indomethacin suppositories
62. Indomethacin and naproxen suppositories in the treatment of rheumatoid arthritis
63. A note on indomethacin suppositories in rheumatic conditions
64. Rectal bleeding and indomethacin
65. Rectal bleeding and indomethacin suppositories
66. Ano-rectal lesions in patients taking suppositories containing non-steroidal anti-inflammatory drugs
67. Solitary rectal lesions due to suppositories containing acetylsalicylic acid and paracetamol
68. Acute perforation of colonic diverticula associated with short term indomethacin
69. Antiinflammatory drugs and bowel perforation and haemorrhage
70. Intestinal perforation associated with slow release indomethacin capsules
71. Lower gastrointestinal side effects of nonsteroidal antiinflammatory drugs
72. Diagnosis of sigmoidovaginal fistula by vaginogram
73. Steroids, non-steroidal anti-inflammatory drugs and serious complications of diverticular disease
74. An association between anti-inflammatory medication and internal pelvic fistulas
75. Complications of diverticular disease and nonsteroidal anti-inflammatory drugs: A prospective study
76. Non-steroidal anti-inflammatory drugs and complicated diverticular disease: a case-control study
77. Prostaglandins, indomethacin and ulcerative colitis (letter)
78. Prostaglandins and the gastrointestinal mucosa: are they important in its function, disease or treatment?
79. Eicosanoids in inflammatory bowel disease-Physiology and pathology
80. Prostaglandin synthesis inhibition in ulcerative colitis. Flurbiprofen compared with conventional treatment
81. NSAID activate quiescent inflammatory bowel disease
82. Relapse of ulcerative proctocolitis during treatment with NSAID
83. Analgesic ingestion and other factors preceding relapse in ulcerative colitis
84. Why do patients with ulcerative colitis relapse?
85. Gastrointestinal perforation following indomethacin in very low birth weight infants
86. Localized intestinal perforation after enteral administration of indomethacin in premature infants
87. Intestinal perforation following enteral administration of indomethacin
88. Osmosin and ileal ulceration: a case report
89. What's new in Osmosin and intestinal perforation?
90. Osmosin tablets
91. Circumferential small-bowel ulcer
92. Ulcerative-obstructive lesions of the small bowel
93. Upper gastrointestinal lesions after potassium chloride supplements: A controlled trial
94. Ileocaecal perforation and bleeding-are NSAID responsible?
95. Drug induced ulceration and perforation of the small bowel
96. Ulcers and strictures of the jejunum in a patient on long term indomethacin therapy
97. Ulceration of the small intestine in a patient with coeliac disease
98. Recurrent small bowel obstruction associated with phenylbutazone
99. Small bowel ulceration in patients receiving NSAIDs for rheumatoid arthritis
100. Ileal stricturing after long term indomethacin treatment
101. Recurrent small bowel obstruction with piroxicam
102. Recurrent small bowel obstruction with piroxicam
103. Diaphragm disease: the pathology of non-steroidal anti-inflammatory drug induced small intestinal strictures
104. Clinico-pathological features of NSAID induced small intestinal strictures
105. Endoscopic description of diaphragm disease induced by non-steroidal anti-inflammatory drugs
106. Enteroscopic diagnosis of small bowel ulceration in patients receiving non-steroidal anti-inflammatory drugs
107. Gastrointestinal damage associated with the use of nonsteroidal antiinflammatory drugs
108. Hypogammaglobulinaemic enteropathy (abstr)
109. Nonsteroidal antiinflammatory drug-induced colonic strictures: a case report
110. Duodenal diaphragm
111. Intraluminal duodenal diverticula
112. Congenital duodenal obstruction
113. Anatomy and embryology of congenital intrinsic obstruction of the duodenum
114. Congenital intestinal atresia and stenosis in the newborn. Observation on its pathogenesis and treatment
115. Uptake and transport of macromolecules by the intestine. Possible role in clinical disorders
116. Sulphasalazine II. Some notes on the discovery and development of salazopyrin
117. Editorial. Rheumatoid arthritis and the gut
118. Rheumatoid arthritis and the gut
119. Reiters syndrome and reactive arthritis in perspective
120. The primary cause of rheumatoid arthritis is an infection. The infectious agent exists in milk
121. Historical aspects of the aetiology of rheumatoid arthritis
122. Treatment of rheumatoid arthritis by colectomy
123. Salazopyrin a new sulphonamide preparation
124. The treatment of poly-arthritis with acid azo compounds
125. Which component of sulphasalazine is active in rheumatoid arthritis?
126. 5-Aminosalicylic acid or sulphapyridine. Which is the active moiety of sulphasalazine in rheumatoid arthritis?
127. Sulphasalazine in inflammatory bowel disease-In memoriam?
128. Possible role of enteric organisms in the pathogenesis of ankylosing spondylitis and other seronegative arthropathies
129. The cross tolerance hypothesis, HLA-B-27 and ankylosing spondylitis
130. Molecular mimicry: Fact or fiction?
131. Autoantibodies to HLA-B27 in sera of HLA-B27 patients with ankylosing spondylitis and Reiters syndrome: molecular mimicry with Klebsiella pneumonia as potential mechanism of autoimmune disease
132. Epidemiology of enteric infections associated with arthritis
133. Transmural passage of inert molecules in health and disease
134. Tests of intestinal permeability in clinical practice
135. Small intestinal permeability
136. Lactulose, 51-Cr labelled ethylenediaminetetraacetate, l-rhamnose and polyethylene glycol 400 as probe markers for assessment of in vivo of human intestinal permeability
137. Intestinal permeability and inflammation in rheumatoid arthritis; effects of non-steroidal anti-inflammatory drugs
138. The effect of NSAIDs and prostaglandins on the permeability of the human small intestine
139. Increased intestinal permeability in patients with rheumatoid arthritis: A side effect of oral non-steroidal anti-inflammatory drug therapy
140. Nichtsteroidale antiphlogistika erohen die darmpermeabilitat
141. 51 Cr-ethylenediaminetetraacetic acid absorption test. Effects of naproxen, a non-steroidal anti-inflammatory drug
142. Misoprostol reduces indomethacin induced changes in human small intestinal permeability
143. The importance of local versus systemic effects of non-steroidal anti-inflammatory drugs to increase intestinal permeability in man
144. The pro-drug sulindac may reduce the risk of intestinal damage associated with the use of conventional non-steroidal antiinflammatory drugs
145. Sucralfate for prevention of naproxen-induced mucosal lesions
146. Cimetidine tablets or suspension in the prevention of gastrointestinal mucosal lesions caused by nonsteroidal anti-inflammatory drugs
147. The effect of polyacrylic acid polymers (carbopol) on small intestinal function and permeability changes caused by indomethacin
148. Glucose and citrate reduce the permeability changes caused by indomethacin in humans
149. Misoprostol reduces indomethacin induced changes in human small intestinal permeability
150. Relevance of intestinal bacteria, prostaglandins and pro-drug administration to NSAID induced increase in gut permeability (abstr)
151. Do nonsteroidal anti-inflammatory drugs increase colonic permeability?
152. The absorption of Chromium-51 labelled ethylenediaminetetraacetate in inflammatory bowel disease
153. 51 Cr EDTA test: a useful test in the assessment of inflammatory bowel disease
154. 99mTc-diethylenetetriaminopentaacetic acid in inflammatory bowel disease
155. Relationship between intestinal permeability to 51 Cr EDTA and inflammatory activity in asymptomatic patients with Crohn's disease
156. Small bowel and colonic permeability to 51 Cr EDTA in patients with active inflammatory bowel disease
157. Nonsteroidal antiinflammatory drug induced inflammation in humans
158. 111-Indium autologous leucocytes in inflammatory bowel disease
159. Quantitative faecal indium-111 labelled leucocyte excretion assessment of disease activity in Crohn's disease
160. indium-111 granulocyte scanning comparison with colonoscopy, histology and faecal indium-111 excretion in assessing disease extent and activity in colitis
161. Clinical investigation of patients with malabsorption and diarrhoea
162. Preliminary evidence for gut involvement in the pathogenesis of rheumatoid arthritis?
163. 111-Indium-labelled polymorphonuclear leucocyte scans in rheumatoid arthritis—an important clinical cause of positive results
164. Small bowel enteroscopy in undiagnosed gastrointestinal blood loss
165. Small bowel enteroscopy (letter)
166. Upper gastrointestinal findings and faecal occult blood in patients with rheumatic disease taking non-steroidal anti-inflammatory drugs
167. Nonsteroidal anti-inflammatory drugs and gastrointestinal bleeding: A case-control study
168. Significance of a positive test for occult blood in stools of patients taking anti-inflammatory drugs
169. Blood and protein loss via small intestinal inflammation induced by nonsteroidal antiinflammatory drugs
170. Intestinal inflammation and bleeding in NSAID enteropathy and inflammatory bowel disease (abstr)
171. NSAID-induced small intestinal inflammation in man
172. NSAID enteropathy: the main site of blood loss in patients on NSAIDs (abstr)
173. Occult faecal blood loss determined by a 51 Cr method and chemical tests in patients referred for colonoscopy
174. Decreased iron absorption in patients with active rheumatoid arthritis, with and without iron deficiency
175. iron absorption in rheumatoid arthritis
176. Anaemia in rheumatoid arthritis the role of iron vitamin B12 for folic acid and erythropoietin responsiveness
177. The anaemia of chronic disorder
178. Serum ferritin and the assessment of iron deficiency in rheumatoid arthritis
179. Study of the molecular mechanism of decreased synthesis of albumin in inflammation
180. Studies of plasma protein metabolism
181. Increasing vascular permeability: A major cause of hypoalbuminaemia in disease and injury
182. 125I albumin
183. Critical analysis of a combined test (75SeHCAT and 58CoB12) of ileal function using a whole body counter
184. Experience with the use of a gastrointestinal marker (51 CrCl3) in a combined study of ileal function using 75SeHCAT and 58CoVitB12 measured by whole body counting
185. Xylose test; effects of aspirin and indomethacin
186. Malabsorption in rheumatoid arthritis
187. Gastrointestinal disturbances in patients with severe rheumatoid arthritis
188. Sulindac-associated small bowel lesion
189. Early cellular events in the pathogenesis of NSAID enteropathy in the rat
190. Enterocyte mitochondrial damage due to NSAID in the rat
191. Effects of salicylate and related compounds in gastric HCl secretions
192. Effects of acetylsalicylic acid on gastric mucosa. II. Mucosal ATP and phosphocreatine content and salicylic effects on mitochondrial metabolism
193. Salicylate and aspirin-induced uncoupling of oxidative phosphorylation in mitochondria isolated from the mucosal membrane of the stomach
194. Occluding junctions and cytoskeletal components in cultured transporting epithelium
195. Effects of cytochalasin D on occluding junctions of intestinal absorptive cells: further evidence that the cytoskeleton may influence paracellular permeability and junctional charge selectivity
196. Occluding junction structure-function relationship in a cultured epithelial monolayer
197. Alterations in intestinal tight junction structure and permeability by cytoskeletal contraction
198. Temporal relationship between cyclooxygenase inhibition, as measured by prostacyclin biosynthesis, and gastrointestinal damage induced by indomethacin in the rat
199. Effects of nonsteroidal anti-inflammatory drugs on gastrointestinal injury and prostanoid generation in healthy volunteers
200. Aspirin can inhibit gastric mucosal cyclo-oxygenase without causing lesions in the rat
201. Role of prostaglandins in preventing gastrointestinal ulceration: Induction of ulcers by antibodies to prostaglandins
202. Small intestinal ulcers and intestinal flora in rats given indomethacin
203. Cytoprotection by prostaglandins
204. Resistance of germ free rats to indomethacin-induced intestinal lesions
205. Role of bacteria in gastric ulceration produced by indomethacin in the rat: cytoprotective action of antibiotics
206. Mucosal lesions induced in the rat intestinal tract by the anti-inflammatory drug Wy-41770 a weak inhibitor of prostaglandin synthesis contrasted with those from the potent prostaglandin inhibitor indomethacin
207. Indomethacin-induced intestinal inflammation
208. Indomethacin induced small intestinal ulceration in the rat (abstr)
209. Early and late phases in the formation by anti-inflammatory drugs of intestinal lesions in the rat
210. Indomethacin-induced intestinal lesions in the rat
211. A comparison of indomethacin with ibuprofen on gastrointestinal mucosal integrity in conventional and germ free rats
212. Recent insight into the mechanism of gastrointestinal tract ulceration
213. Enterohepatic circulation of indomethacin and its role in intestinal irritation
214. The enterohepatic circulation of some anti-inflammatory drugs may cause intestinal ulceration in the rat
215. Metronidazole reduces inflammation and blood loss in NSAID enteropathy
216. Gastric ulceration induced by nonsteroidal antiinflammatory drugs is a neutrophil dependent process
217. A monoclonal antibody against the CD 18 leucocyte adhesion molecule prevents indomethacin-induced gastric damage in the rabbit
218. Leucocyte adherence to venular endothelium during ischemia perfusion
219. Intestinal microvascular exchange in the rat during luminal perfusion with N-formyl-methionyl-leucyl-phenylalanin
220. Neutrophils in human disease
221. Tissue destruction by neutrophils
222. The electron transport chain of the microbicidal oxidase of phagocytic cells and its involvement in the molecular pathology of chronic granulomatous disease
223. Leucocyte locomotion: determinants of locomotor capacity, chemotaxis and chemokinesis
224. The treatment of non-steroidal anti-inflammatory drug induced enteropathy
225. Intestinal permeability, NSAID enteropathy and inflammatory bowel disease
226. Treatment of small intestinal Crohn's disease with sulphasalazine (abstr)
227. Treatment of NSAID induced small intestinal inflammation (abstr)